EGFR and metastatic colorectal cancer: Cetuximab and panitumumab are FDA‐approved monoclonal antibodies against epidermal growth factor receptor (EGFR), which are commonly used for patients with RAS wild‐type metastatic colorectal cancer (mCRC) 1.